Certain people risk severe or life-threatening reactions if they consume these products, according to an official alert.
UPDATE (January 5, 2026): The future of the Food and Drug Administration (FDA) 's proposed ban on hair-straightening products ...
Stocktwits on MSN
GH Research stock grabs retail spotlight ahead of FDA update on depression treatment
GH Research is scheduled to update on the FDA status of GH001 and outline its global Phase 3 plans for treatment-resistant ...
Flow Space on MSN
Update: FDA approves oral version of Wegovy, first GLP-1 pill approved specifically for weight management
Just before the end of 2025, an oral version of a GLP-1 drug specifically used for weight management moved much closer to reality. On December 22, the U.S. Food and Drug Administration (FDA) approved ...
The FDA issued a CRL for ONS-5010, citing the need for additional confirmatory efficacy evidence despite previous trials ...
5. Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting ...
A Boxed Warning was included in the prescribing information highlighting the risk of serious liver injury and acute liver failure. The Food and Drug Administration (FDA) has approved new safety ...
Omeros (OMER) stock in focus as the FDA approves its lead asset as Yartemlea for a complication related to stem cell ...
Ali Mahdavi - Spinnaker Capital Markets Inc. Scott McAuley - Paradigm Capital Inc., Research Division Greetings. Welcome to Spectral Medical Year-end 2025 Corporate Update End Year Review Call.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback